NeuroSense Therapeutics Ltd.
NRSN · XNASCIK 1875091fmd_1CWEBJ6G4S568N65AE5ZKTFTF6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 12 periods
Latest annual · FY2025
Millions- Free cash flow
- (8)
Daily close · NRSNIEX trades only
Nov 09, 2026 to Nov 10, 2026 · 2 sessions1.72 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
NeuroSense Therapeutics Ltd. (NRSN) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$11.1 million | -$9.9 million | 20-F 2026-03-31 · proof | |
| Net income | -$11.1 million | -$10.2 million | 20-F 2026-03-31 · proof | |
| Cash from operating activities | -$7.7 million | -$10.1 million | 20-F 2026-03-31 · proof | |
| Free cash flow | -$7.7 million | -$10.1 million | 20-F 2026-03-31 · proof | |
| Total assets | $1 million | $4.6 million | -77.5% | 20-F 2026-03-31 · proof |
| Total liabilities | $2.6 million | $2 million | +29.9% | 20-F 2026-03-31 · proof |
| Cash and cash equivalents | $166,000 | $3.4 million | -95.1% | 20-F 2026-03-31 · proof |
- What was NeuroSense Therapeutics Ltd. (NRSN)'s operating income in fiscal 2025?
- NeuroSense Therapeutics Ltd. (NRSN) reported operating income of -$11.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$9.9 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was NeuroSense Therapeutics Ltd. (NRSN)'s net income in fiscal 2025?
- NeuroSense Therapeutics Ltd. (NRSN) reported net income of -$11.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$10.2 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was NeuroSense Therapeutics Ltd. (NRSN)'s cash from operating activities in fiscal 2025?
- NeuroSense Therapeutics Ltd. (NRSN) reported cash from operating activities of -$7.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$10.1 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was NeuroSense Therapeutics Ltd. (NRSN)'s free cash flow in fiscal 2025?
- NeuroSense Therapeutics Ltd. (NRSN) reported free cash flow of -$7.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$10.1 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are NeuroSense Therapeutics Ltd. (NRSN)'s total assets?
- As of Dec 31, 2025, NeuroSense Therapeutics Ltd. (NRSN) reported total assets of $1 million, against $4.6 million a year earlier (-77.5%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are NeuroSense Therapeutics Ltd. (NRSN)'s total liabilities?
- As of Dec 31, 2025, NeuroSense Therapeutics Ltd. (NRSN) reported total liabilities of $2.6 million, against $2 million a year earlier (+29.9%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are NeuroSense Therapeutics Ltd. (NRSN)'s cash and cash equivalents?
- As of Dec 31, 2025, NeuroSense Therapeutics Ltd. (NRSN) reported cash and cash equivalents of $166,000, against $3.4 million a year earlier (-95.1%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NRSN&period_type=annual&limit=5"Information only, not investment advice.